4596 Kubota Pharmaceutical Holdings
- 71
- 00.00%
Kubota Pharmaceutical Holdings News
Kubota Pharmaceutical HD---1Q strengthens preparations for Kubota Glass sales expansion and product improvement/service creation
Kubota Pharmaceutical Holdings ＜4596＞ announced consolidated financial results (IFRS) for the 1st quarter (January to March 24) of the fiscal year ending 2024/12 on the 14th. Business revenue decreased 2.8% from the same period last year to 0.05 billion yen, operating loss was 337 million yen (loss of 445 million yen in the same period last year), loss before income tax was 343 million yen (loss of 444 million yen), and quarterly losses attributable to owners of parent companies were 343 million yen (loss of 444 million yen). Wearable myopia device in medical devices
KUBOTA PHARMACEUTICAL HLDGS: Confirmation Letter
KUBOTA PHARMACEUTICAL HLDGS: Summary of Financial Results for the 1st Quarter of the Fiscal Year Ending December 2024/12 [IFRS] (Consolidated)
KUBOTA PHARMACEUTICAL HLDGS: Quarterly Report - 10th Term 1st Quarter (2024/01/01 - 2024/03/31)
Kubota Pharmaceutical HD --- New Patent Acquired in US
Kubota Pharmaceutical Holdings ＜4596＞ announced on the 9th that its subsidiary Kubota Vision Ink (Washington, USA) has obtained a new patent in the United States. Acquired patents relating to the at-home/remote ophthalmology medical retinal monitoring device (Patient Based Ophthalmology Suite) “eyeMO” and Kubota glasses technology. The name of the first invention is SYSTEM AND METHOD FOR OPTICAL COHER
Emerging Market Stock Digest: Matsuya R&D continues to increase drastically, and Metalial continues to increase drastically for 5 days
Significant continuous growth. The operating profit forecast for the fiscal year ending 24/3 has been revised upward from the previous 1200 billion yen to 1,270 billion yen (previous fiscal year results 611 million yen).
Kubota Pharmaceutical HD --- Significant Continued Development, Specific Clinical Research on Retinal Monitoring Devices for Home/ Remote Ophthalmology Care Approved
Significant continued growth. It has been announced that it has received approval from the Accredited Clinical Research Review Committee for specific clinical research using the at-home/remote ophthalmology retinal monitoring device “eyeMO” developed by the US subsidiary Kubota Vision Inc. It is carried out at Shinshu University Medical School Hospital and is funded by Chugai Pharmaceutical ＜4519＞. After carrying out a feasibility study (feasibility study), patients with diabetic macular edema will verify whether it is possible to use the device at the patient's home.
Kubota Pharmaceutical HD Research Memo (10): Since the development stage continues for the time being, we are raising funds for business activities from the stock market
The total assets of Kubota Pharmaceutical Holdings＜4596＞ at the end of the 2023/12 fiscal year decreased 1,402 million yen from the end of the previous fiscal year to 3,016 million yen. Looking at the main factors of change, current assets, cash and cash equivalents decreased by 1,281 million yen to 2,767 million yen due to expenditure of business activity funds, and inventory assets increased by 29 million yen to 36 million yen.
Kubota Pharmaceutical HD Research Memo (9): Earnings forecasts for the fiscal year ending 2024/12 are not disclosed, but costs are suppressed except for some businesses
The consolidated financial results for the fiscal year ended 2023/12 of Kubota Pharmaceutical Holdings ＜4596＞ were 39 million yen (up 31 million yen from the previous fiscal year) in terms of business revenue, 1,504 million yen (same reduction of 534 million yen) in operating losses, 1,489 million yen (same reduction of 526 million yen) due to loss before income taxes, and 1,489 million yen (same reduction of 526 million yen) due to net loss attributable to owners of the parent company.
Kubota Pharmaceutical HD Research Memo (8): Projects for NASA are suspended, but there is a possibility that they will resume due to a change of administration
Kubota Pharmaceutical Holdings ＜4596＞ signed a development contract with NASA in 2019 regarding a development project for the ultra-compact ophthalmic diagnostic device “Swept Source-OCT (hereinafter, SS-OCT)” to perform research on eye diseases caused by space flight, and completed the first phase development mission in early 2020.
Kubota Pharmaceutical HD Research Memo (7): Emixstat hydrochloride is considering aiming for marketing using an early approval system, including in Japan
Stargard disease is a genetic disorder of the retina, and poor eyesight and color vision impairment from childhood to adolescence are the main symptoms. Also known as juvenile macular degeneration, it is estimated that there are less than 150,000 patients in Europe, America, and Japan*1, and the incidence rate is 1 rare disease in 80 to 10,000 people.
Kubota Pharmaceutical HD Research Memo (6): “EyeMo” has signed an agreement with a major Indian company for joint development
“EyeMO” * is an at-home/remote ophthalmology medical retinal monitoring device (Patient Based Ophthalmology Suite) for patients with retinal diseases such as wet age-related macular degeneration and diabetic macular edema. It is a system where patients themselves measure and photograph the thickness of the retina at home, the doctor in charge confirms the data via the internet, and diagnoses whether treatment (medication) is necessary.
Kubota Pharmaceutical HD Research Memo (5): “Kubota Glass” promotes efforts to improve customer satisfaction (2)
Sales of “Kubota Glass” began in 2022/8 as a “glasses-type AR device that reproduces outdoor activities” in Japan (sales price 770,000 yen including tax) *. At the beginning of sales of the made-to-order type, there was a shortage of semiconductors, and the lead time from order to delivery required about 3 months, but recently it has been shortened to 1 to 2 months due to the shortage of semiconductors.
Kubota Pharmaceutical HD Research Memo (4): “Kubota Glass” promotes efforts to improve customer satisfaction (1)
Kubota Pharmaceutical Holdings ＜4596＞ is focusing on the development of Kubota glasses technology which is expected to have the effect of suppressing or improving the progression of myopia. The types of myopia are classified into refractive myopia, axial myopia, false myopia, nuclear myopia, etc., but most of them are called axial myopia, and it is a mechanism where the retina moves behind the focus due to extension of the ocular axis length, making it difficult to see far away.
Kubota Pharmaceutical HD Research Memo (3): With the vision of “eradicating blindness from around the world,” a myopia eradication project has also started
Kubota Pharmaceutical Holdings ＜4596＞ has a vision of “eradicating blindness from around the world,” and in addition to developing medical devices utilizing cutting-edge digital technology and developing therapeutic agents for eye diseases for which there is no effective treatment, it has started the myopia eradication project “ZERO Diopter Project” * from 2023. As a development strategy, we are working to diversify business risk and increase corporate value by forming two business portfolios with different risk-return characteristics, pharmaceuticals and medical devices.
Kubota Pharmaceutical HD Research Memo (2): Aiming to develop innovative pharmaceuticals and medical devices specializing in the field of ophthalmology
Dr. Kubota Ryo (Kubota), a researcher and ophthalmologist, established the former Acucera Inc., in 2002 in Seattle, USA, for the purpose of developing pharmaceuticals and medical devices specialized in the field of ophthalmology. After being listed as a foreign stock on the Tokyo Stock Exchange in 2014/2, the Japanese corporation was converted into a holding company as Kubota Pharmaceutical Holdings Co., Ltd. by a triangular merger method in 2016/12, and re-listed as TSE Mothers domestic stock (the former Acucella Inc., was delisted at the end of November of the same year).
Kubota Pharmaceutical HD --- 2024 is a policy to work on product improvements etc. of “Kubota Glass”
Kubota Pharmaceutical Holdings ＜4596＞ has a vision of “eradicating blindness from around the world,” and is working on the development of innovative therapeutic agents and medical devices specialized in the ophthalmology field in order to promote the digitalization of medical care. The main development pipelines are the wearable myopia device “Kubota glasses,” which are expected to have the effect of suppressing or improving the progression of myopia, and the home/remote ophthalmology monitoring device “eyeMO (Aimo)” for patients with retinal diseases such as age-related macular degeneration, and Stargal
Kubota Pharmaceutical Adjusts 2023 Financial Results Following Reevaluation
Kubota Pharmaceutical Holdings (TYO:4596) has identified necessary corrections in its consolidated financial results for the year ended Dec. 31, 2023 (under IFRS) following a re-evaluation of the reco
Kubota Pharma FY Loss Y1.49B Vs Loss Y2.02B
Kubota Pharmaceutical Holdings Co. Ltd. (4596.TO) Japan Year Ended December 31 GROUP 2023 2022 Revenue Y40.00 mln Y8.00 mln Operating Profi
Analysis
Price Target
No Data
